With $3bn Viela Acquisition, Horizon Builds A Pipeline
Executive Summary
Horizon will gain the commercial product Uplizna and three pipeline products for rare diseases, where it can build on its success with Tepezza. Horizon is also interested in Viela's R&D team.
You may also be interested in...
ArriVent Is Second Positive IPO Of 2024 After CG Oncology’s Debut
ArriVent launched the second biopharma initial public offering of 2024, closing above its IPO price on its first day and grossing $175m – and keeping the financial market mood optimistic.
Horizon Scores In Second Round Of Sjögren’s Trial A Month After Amgen Buyout
The company announced positive results in the second population of its Phase II study of dazodalibep in patients with Sj
Horizon Makes The Case For An Ambitious $10Bn Sales Goal
The rare disease specialist held its first R&D day since acquiring Viela Bio and laid out the development strategy for four mid-stage drugs to drive long-term growth.